Cargando…

Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria

AIMS: The aim was to investigate the QT effect of a single dose combination regimen of piperaquine phosphate (PQP) and a novel aromatic trioxolane, OZ439, for malaria treatment. METHODS: Exposure–response (ER) analysis was performed on data from a placebo-controlled, single dose, study with OZ439 an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Darpo, Borje, Ferber, Georg, Siegl, Peter, Laurijssens, Bart, Macintyre, Fiona, Toovey, Stephen, Duparc, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Clinical Trials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4594707/ https://www.ncbi.nlm.nih.gov/pubmed/25966781 http://dx.doi.org/10.1111/bcp.12680

Ejemplares similares

Anti-malarial ozonides OZ439 and OZ609 tested at clinically relevant compound exposure parameters in a novel ring-stage survival assay
por: Walz, Annabelle, et al.
Publicado: (2019)

Monoclonal Antibodies That Recognize the Alkylation Signature of Antimalarial Ozonides OZ277 (Arterolane) and OZ439 (Artefenomel)
por: Jourdan, Joëlle, et al.
Publicado: (2015)

Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial
por: Phyo, Aung Pyae, et al.
Publicado: (2016)

Encapsulation of OZ439 into Nanoparticles for Supersaturated Drug Release in Oral Malaria Therapy
por: Lu, Hoang D., et al.
Publicado: (2018)

Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QT(c) interval in healthy subjects
por: Darpö, Börje, et al.
Publicado: (2013)

First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials
por: Moehrle, Joerg J, et al.
Publicado: (2013)

Spray drying OZ439 nanoparticles to form stable, water-dispersible powders for oral malaria therapy
por: Ristroph, Kurt D., et al.
Publicado: (2019)

Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers
por: McCarthy, James S., et al.
Publicado: (2016)

The Curious Case of the OZ439 Mesylate Salt: An Amphiphilic Antimalarial Drug with Diverse Solution and Solid State Structures
por: Clulow, Andrew J., et al.
Publicado: (2018)

Lipid Compositions in Infant Formulas Affect the Solubilization of Antimalarial Drugs Artefenomel (OZ439) and Ferroquine during Digestion
por: Salim, Malinda, et al.
Publicado: (2020)

Impact of Ferroquine on the Solubilization of Artefenomel (OZ439) during in Vitro Lipolysis in Milk and Implications for Oral Combination Therapy for Malaria
por: Salim, Malinda, et al.
Publicado: (2019)

The New S7B/E14 Question and Answer Draft Guidance for Industry: Contents and Commentary
por: Darpo, Borje, et al.
Publicado: (2021)

A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria
por: Macintyre, Fiona, et al.
Publicado: (2017)

New developments in anti-malarial target candidate and product profiles
por: Burrows, Jeremy N., et al.
Publicado: (2017)

Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects
por: Täubel, Jörg, et al.
Publicado: (2016)

Erratum to: New developments in anti-malarial target candidate and product profiles
por: Burrows, Jeremy N., et al.
Publicado: (2017)

Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Omadacycline on QT/QTc Intervals in Healthy Subjects
por: Darpo, Borje, et al.
Publicado: (2019)

Dihydroartemisinin‐piperaquine for treating uncomplicated Plasmodium falciparum malaria
por: Zani, Babalwa, et al.
Publicado: (2014)

Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia
por: Assefa, Ashenafi, et al.
Publicado: (2022)

Diurnal QT analysis in patients with sotalol after cardioversion of atrial fibrillation
por: Lenhoff, Hanna, et al.
Publicado: (2021)

Efficacy and Day 7 Plasma Piperaquine Concentrations in African Children Treated for Uncomplicated Malaria with Dihydroartemisinin-Piperaquine
por: Zongo, Issaka, et al.
Publicado: (2014)

Revefenacin, a Long‐Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo‐ and Positive‐Controlled Thorough QT Study
por: Borin, Marie T., et al.
Publicado: (2019)

The Wizard of Oz /
por: Baum, L. Frank (Lyman Frank), 1856-1919
Publicado: (1982)

Thorough QT/QTc Evaluation of the Cardiac Safety of Secnidazole at Therapeutic and Supratherapeutic Doses in Healthy Individuals
por: Darpo, Borje, et al.
Publicado: (2017)

Correction: Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia
por: Assefa, Ashenaf, et al.
Publicado: (2023)

Evolution of genetic markers for drug resistance after the introduction of dihydroartemisinin–piperaquine as first-line anti-malarial treatment for uncomplicated falciparum malaria in Indonesia
por: Rahmasari, Farindira Vesti, et al.
Publicado: (2023)

Pharmacokinetics of Piperaquine in Pregnant Women in Sudan with Uncomplicated Plasmodium falciparum Malaria
por: Adam, Ishag, et al.
Publicado: (2012)

Blackwater fever in an uncomplicated Plasmodium falciparum patient treated with dihydroartemisinin-piperaquine
por: Lon, Chanthap, et al.
Publicado: (2014)

Therapeutic efficacy of dihydroartemisinin-piperaquine combination for the treatment of uncomplicated malaria in Ghana
por: Abuaku, Benjamin, et al.
Publicado: (2023)

Potential strategy for assessing QT/QTc interval for drugs that produce rapid changes in heart rate: Electrocardiographic assessment of the effects of intravenous remimazolam on cardiac repolarization
por: Kleiman, Robert B., et al.
Publicado: (2020)

The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects
por: Mueller, Markus S., et al.
Publicado: (2020)

African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker
por: Leroy, Didier, et al.
Publicado: (2019)

In vitro interaction of artemisinin derivatives or the fully synthetic peroxidic anti-malarial OZ277 with thapsigargin in Plasmodium falciparum strains
por: Abiodun, Oyindamola O, et al.
Publicado: (2013)

Population Pharmacokinetic Assessment of the Effect of Food on Piperaquine Bioavailability in Patients with Uncomplicated Malaria
por: Tarning, Joel, et al.
Publicado: (2014)

Adherence to Dihydroartemisinin-Piperaquine Treatment among Patients with Uncomplicated Malaria in Northern Ghana
por: Oduro, Abraham Rexford, et al.
Publicado: (2019)

Efficacy and Safety of Artemisinin-Piperaquine for the Treatment of Uncomplicated Malaria: A Systematic Review
por: Wang, Qi, et al.
Publicado: (2020)

El mago de Oz /
por: Baum, Lyman Frank, 1856-1919
Publicado: (1987)

El mago de Oz /
por: Baum, Lyman Frank, 1856-1919
Publicado: (1990)

El mago de Oz
por: Baum, L. Frank (Lyman Frank), 1856-1919
Publicado: (2013)

Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies
por: Mendzelevski, Boaz, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_a2sk4gb4ds9ji6eelqau00a7fs